Application No.: 09/679,776 2 Docket No.: 02650/100F966-US2

AMENDMENTS TO THE CLAIMS

Please amend the claims so that they read as follows:

Claims 1-31 (canceled)

32 (Currently Amended). A method of inducing an immune response to a tumor in a subject, which method comprises <u>intradermally or subcutaneously</u> administering total tumor cell RNA to epidermal <u>cutaneous</u> cells of the subject *in vivo*, in an amount effective to elicit an immune response against the tumor, wherein the total tumor cell RNA is from tumor cells from the subject.

33 (Previously Presented). The method of claim 32, wherein the tumor is a fibrosarcoma tumor.

34 (Previously Presented). The method of claim 32, wherein the immune response reduces or inhibits growth of the tumor.

35 (Currently Amended). A method for protecting a subject from a cancer, which method comprises <u>intradermally or subcutaneously</u> delivering an immunologically effective amount of total tumor cell RNA to <u>epidermal cutaneous</u> cells of the subject *in vivo*, wherein the total tumor cell RNA is taken from a <u>an autologous</u> tumor associated with the cancer.

36 (Previously Presented). The method of claim 35, further comprising delivering an immunostimulatory amount of an immune activating or inflammatory cytokine to the subject.

Claims 37- 42 (Canceled).

43 (Currently Amended). A method of inducing immune tolerance to an antigen in a subject, which method comprises intraveneously administering <u>RNA</u> which comprises antigen RNA to the subject in an amount effective to elicit immune tolerance against the antigen, wherein the antigen is an <u>autoantigen</u>, an <u>allegenic</u> transplant tissue antigen.

44 (Previously Presented). The method of claim 43, wherein the RNA is total cellular RNA from tissues containing the antigen.

Application No.: 09/679,776 3 Docket No.: 02650/100F966-US2

45 (Previously Presented). The method of claim 43, wherein the RNA is total cellular mRNA from tissues containing the antigen.

46 (Previously Presented). The method of claim 43, wherein the RNA is mRNA encoding the antigen.

Claims 47-49 (Canceled).

50 (New). The method of claim 43, wherein the transplant tissue antigen is from an organ or blood cells.

51 (New). The method of claim 43, wherein the transplant tissue antigen is skin tissue.

52 (New). The method of claim 43, wherein the transplant tissue is from a heart, lung, liver, kidney, or pancreas.

53 (New). The method of claim 43, wherein the transplant tissue is from platelets, lymphocytes, leukocytes, or red blood cells.